Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 6891 (MIR6891) is a short (~22 nucleotide), non-coding RNA transcript derived from intron 4 of the HLA-B gene, classifying it as a mirtron microRNA[1][2][3]. It is processed by the Dicer enzyme into mature miR-6891-5p and miR-6891-3p strands. As with other microRNAs, it participates in post-transcriptional gene silencing by binding target mRNA transcripts—most notably, it regulates IGHA1 and IGHA2, influencing immunoglobulin A (IgA) expression in B lymphocytes[1]. MIR6891 may have a role in immune function and selective IgA deficiency, a condition characterized by low or absent IgA. No drugs currently target MIR6891, it is not an established therapeutic receptor or enzyme, and there is no known direct link to major diseases beyond immunological processes[1][2][3].
RNA-induced silencing complex (RISC) loading for mRNA degradation or translational repression Post-transcriptional inhibition of IGHA1 and IGHA2 via non-canonical binding to 3’UTR
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 6891 (MIR6891).